Fasting during ramadan: new study checks safety for adrenal patients
NCT ID NCT07367425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether fasting during Ramadan is safe for people with primary adrenal insufficiency, a condition where the adrenal glands don't make enough hormones. Researchers will monitor 35 patients for low blood sugar and dehydration during two weeks of fasting and two weeks of non-fasting. The goal is to understand the risks and help guide safe fasting practices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 35 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * subjects with primary adrenal insufficiency known for at least one year, treated with a glucocorticoid and a mineralocorticoid, who wish to fast during Ramadan 2026. Exclusion Criteria: * presence of diabetes, renal, hepatic, cardiac, or respiratory insufficiency; use of hypoglycemic agents (sulfonylureas), diuretics, use of any glucocorticoid other than the prescribed replacement therapy; poor disease control (asthenia, malaise, hyperpigmentation, discontinuation of treatment, etc.); pregnancy; breastfeeding; menstruation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital La Rabta
Tunis, Tunisia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a water schedule beat hydration lessons for teen athletes?
- Two hydrocortisone pills go Head-to-Head in adrenal insufficiency trial
- Can wearable glucose monitors reveal hidden risks in dialysis patients with diabetes?
- Will a tiny sensor boost Well-Being in type 2 diabetes?
- What's it really like to wear a glucose monitor? a study asks patients
- Can a drink beat water for rehydration? a new trial puts electrolyte formulas to the test